Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders To Or Intolerant Of TNF-alpha Antagonists

Trial Profile

A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders To Or Intolerant Of TNF-alpha Antagonists

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2019

At a glance

  • Drugs Sarilumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-TARGET; SARIL-RA-TARGET; TARGET
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Jun 2019 Results describing patient-level, cross-walked PROMIS-fatigue and scoring service 13- and 10-item PROMIS-fatigue scores from TARGET, MOBILITY and MONARCH presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results of a post hoc analysis from TARGET and MONARCH studies presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results assessing long-term safety from the sarilumab clinical development program from MOBILITY (NCT01061736), TARGET (NCT01709578), ASCERTAIN (NCT01768572), EASY (NCT02057250), COMPARE (NCT01764997), ACT11575 (NCT01217814), MONARCH (NCT02332590), ONE (NCT02121210), and the open-label extension EXTEND (NCT01146652) trials presented at the 20th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top